In vivo comparison within the enantiomers of [18F]PM-PBB3

In vivo comparison within the enantiomers of [18F]PM-PBB3, a PET ligand for diverse tauopathies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs031190114

Enrollment

Registered

2019-10-21

Start date

2019-12-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild cognitive impairment, Alzheimers disease, progressive supranuclear palsy, and so on.

Interventions

Injection of [18F]PMPBB3 and PET scan

D049268

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (efficacy) Healthy subjects and subjects with mild cognitive impairment, Alzheimer's disease, progressive supranuclear palsy, corticobasal syndrome or frontotemporal degeneration over 20 years of age (safety) Healthy subjects over 50 years of age

Exclusion criteria

Exclusion criteria: (efficacy) 1.Subjects with any organic brain disorder. 2.Subjects with any substance-related disorders. 3.Subjects who has a serious disease complication or history. 4.Subjects with metallic medical device in the body. 5.Subjects with tattoo. 6.Subjects with severe claustrophobia. 7.Subjects with pregnancy or breastfeeding. 8.Subjects who has participated in other study in recent 6 months. 9.Subjects with a history of allergy to heparin and local anesthetics.(applied to (efficacy)) 10.Subjects who has taken anticoagulants. (applied to (efficacy)) 11.Subjects who is considered to be inappropriate to participate in the study. (safety) 1.Subjects with any organic brain disorder. 2.Subjects with any substance-related disorders. 3.Subjects who has a serious disease complication or history. 4.Subjects with metallic medical device in the body. 5.Subjects with tattoo. 6.Subjects with severe claustrophobia. 7.Subjects with pregnancy or breastfeeding. 8.Subjects who has participated in other study in recent 6 months. 9.Subjects who is considered to be inappropriate to participate in the study.

Design outcomes

Primary

Measure	Time frame
(efficacy) Differeces of pharmacokinetics, distibution of volume, quantification, and off-target binding among the enantiomers of [18F]PM-PBB3 (safety) Effective dose of the favoranble enantiomers of [18F]PM-PBB3 in human	—

Secondary

Measure	Time frame
(efficacy) Clinical effects of [18F]PM-PBB3 in human	—

Contacts

Public ContactKenji Tagai

Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate, National Institutes for Quantum Science and Technology (QST)

tagai.kenji@qst.go.jp+81-43-206-3251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026